Immunovia-banner.jpg

IMMUNOVIA

About us

Immunovia, Inc. is the exclusive provider of the IMMray® PanCan-d test, a blood test for the early detection of pancreatic adenocarcinoma (PDAC).

 
IMMray-1.jpg
 

The IMMray PanCan-d test relies on the IMMray microarray technology, where single chain fragment antibodies are produced and then printed onto a slide in a measured amount as a microarray of different antibody biomarkers. 14 microarrays are printed on each slide.

IMMray-2.jpg

When a patient’s serum sample is received at Immunovia, Inc., the patient’s serum is biotinylated and then applied to the microarray; the microarray is scannedusing a fluorescence scanner to measure antibody responses to patient serum; and then antibody response levels are entered into an algorithm to determine a result of “High-Risk Signature Present”, “Negative for High-Risk Signature” or Borderline result.

social-section.jpg
 TALK TO US 

Chat Live with us on August 6th, 2021

ecce35_35af1cb37f704573a3aa9b483ae08b12_mv2_d_4500_3000_s_4_2.webp
JOIN THE LIVE EVENT

IMMUNOVIA, Inc.

immunoviainc.com

26 Forest Street, Suite 110 Marlborough, MA 01752

MEAGAN LUIPOLD

Meagan.luipold@immunovia.com

508-613-8212

  • LinkedIn
  • Facebook
  • Instagram
  • Twitter

Return to the MAGIC 2021 Conference Streaming

 
 

Search tags: Pancreatic Cancer, Laboratory Test, Biomarkers, Blood Test